ClinicalTrials.gg
RecruitingNCT07718724PRECISIONUpdated Sep 24, 2026

Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist

An interventional study of Intervention group in Uncontrolled Asthma, sponsored by AstraZeneca. Recruiting at 20 sites in China. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by AstraZeneca · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
540
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
64th of 248
540 · median 175
Started
2026
with 9 others
No phase
6 of 359
2 open now
Primary completion
2028-04
later than 19 of 27 live
Registered
356th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 64th largest by planned enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 with no phase, reaches primary completion later than 19 of the 27 other live ones, and was the 356th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA.

  • The intervention period will be up to 48 weeks;
  • The frequency of follow-up is every 12 weeks.
Read the detailed description

This study is a prospective, multicenter, cluster-randomized trial conducted in China, designed to evaluate the application effect of Guideline-Directed Medical Therapy (GDMT). A scientific committee will be established to be responsible for developing GDMT educational materials and facilitating the implementation of GDMT. The study will introduce a GDMT pathway in intervention group aimed at guiding physicians and specialized nurses in the diagnosis and management of participants who are receiving medium- to high-dose ICS-LABA therapy but have uncontrolled asthma.

This study plans to include approximately 60 study sites and consecutively recruit approximately 540 participants. These sites will cover as many provinces and cities as possible to balance geographical distribution. For the 60 selected sites meeting the hospital qualification requirements, a stratified block randomization method will be used, with the stratification factor being the prior written diagnosis rate for severe asthma (the proportion of severe asthma written diagnoses among patients with asthma on medium-to-high dose ICS-LABA). Sites will be randomly allocated in a 1:1 ratio to either the intervention group or the control group (30 sites per group). To minimize selection bias, each site will consecutively enroll 9 participants who meet all inclusion criteria and have provided signed informed consent. All participants must complete the baseline study assessments before entering the study. This is a cluster-randomized interventional study, with an expected duration of 48 weeks. The intervention is implemented at the hospital level. Participants in the two groups will be managed as follows:

  • Intervention Group: Physicians at the study sites will receive GDMT-related training and manage participants according to the GDMT diagnosis and treatment pathway.
  • Control Group: Physicians at the study sites will manage participants using usual clinical care.

Participant data (including but not limited to: demographic characteristics, number of exacerbations, asthma medication use, ACT scores, pulmonary function, SGRQ scores, medical costs) will be collected according to the Schedule of Study Activities.

The benefits and effectiveness of GDMT will be determined by assessing changes in physician behavior, improvements in patient outcomes, and savings in healthcare resources.

The intervention consists of 5 distinct components: routine training, GDMT education, clinical monitoring, targeted training, and material revision.

03

Conditions studied

  • Uncontrolled Asthma

Browse trials for

Keywords

  • PRECISION
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before any study-related procedures;
  2. Age 18-75 years (inclusive) at Visit 0;
  3. Have a written diagnosis of asthma for more than 6 months prior to Visit 0, and have evidence of reversible airflow limitation prior to Visit 0. Evidence of reversible airflow limitation includes: post-bronchodilator increase in (FEV1) of ≥12% and an absolute increase of ≥200 mL, or average daily diurnal Peak Expiratory Flow (PEF) variability >10%, or an increase in FEV1 of ≥12% and an absolute increase of ≥200 mL compared to baseline after 4 weeks of treatment containing ICS, or a positive bronchial provocation test record. If no prior record exists, reversible airflow limitation must be confirmed and documented via a bronchodilator test during Visit 0;
  4. Under the usage of MD/HD ICS-LABA;
  5. Experienced one or more exacerbations within the past year;

Exacerbation is defined as meeting any of the following criteria:

  1. Use of systemic (or a temporary increase in the stable dose of baseline oral corticosteroids) for at least 3 days; a single injection of a depot long-acting corticosteroid can be considered equivalent to a 3-day course of systemic corticosteroids;
  2. An emergency department or urgent care site visit for asthma (defined as being evaluated and treated in the emergency department or urgent care site for \< 24 hours) requiring the use of systemic corticosteroids for at least 3 days (as described above);
  3. Hospitalization for asthma (defined as admission to a hospital and/or being evaluated and treated in a healthcare facility for ≥ 24 hours).

Exclusion criteria

Exclusion Criteria:

  1. Previous written diagnosis as "Severe Asthma"; Diagnosis of Severe Asthma includes: severe asthma, or related diagnoses containing "severe asthma", or "bronchial asthma (severe)".
  2. Imaging suggests the presence of bullae or cystic bronchiectasis;
  3. Currently participating in other interventional studies;
  4. Previous use of biologics for asthma treatment;
  5. Using systemic for other diseases;
  6. History of respiratory tract infection within 4 weeks prior to Visit 0 (upper respiratory tract infections and lower respiratory tract infections);
  7. Any significant disease or disorder (e.g., cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine/metabolic, malignant, psychiatric, or significant physical impairment, etc.) which, in the opinion of the investigator, may put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to comply with GDMT.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The intervention will be implemented at the hospital level.

    Behavioral: Intervention group

  • No intervention
    Control group

    No intervention action will be taken at hospital level, even patient level.

Interventions

  • BehavioralIntervention group

    The GDMT pathway targets physicians and specialized nurses for implementation. It ensures that physicians at intervention groups conduct standardized diagnosis and treatment following GDMT, and that specialized nurses deliver patient education and follow-up reminders according to GDMT. This is achieved through regular knowledge training, provision of a series of reminder/support tools, and a bi-weekly (every 12 weeks) monitoring, and feedback system for Key Performance Indicators (KPIs).

06

What researchers measure

Primary outcomes

  1. Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24

    To evaluate the effect of GDMT education on diagnosis rates of severe asthma

    Time frame: Week 24

  2. Difference in the annualized asthma exacerbation rate between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on asthma exacerbations

    Time frame: Week 48

Secondary outcomes

  1. Difference in the proportion of participants with asthma exacerbation between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Week48

  2. Difference in the change in mean ACT score from baseline between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Baseline, week 48

  3. Change in mean ACT score from baseline in the intervention group at Week 24 and 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Baseline, week 24, week 48

  4. Change in the proportion of participants achieving asthma symptom control (ACT ≥20) from baseline in the intervention group at Week 24 and 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Baseline, week 24, week 48

  5. Difference in the proportion of participants with asthma symptom control (ACT ≥20) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Week 48

  6. Difference in the proportion of participants achieved the Minimal Clinically Important Difference (MCID) in asthma symptom control (ACT improvement ≥3 points) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Week 48

  7. The proportion of participants achieved ACT MCID (ACT improvement ≥3 points) in the intervention group at Week 24 and 48

    To evaluate the effect of GDMT education on asthma control

    Time frame: Week 24, week 48

  8. Difference in pre-bronchodilator Forced Expiratory Volume in 1 second (Pre-BD FEV1) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on pulmonary function

    Time frame: Week 48

  9. Change in pre-bronchodilator FEV1 (Pre-BD FEV1) from baseline in the intervention group at Week 24 and 48

    To evaluate the effect of GDMT education on pulmonary function

    Time frame: Baseline, week 24, week 48

  10. Difference in the proportion of participants with combined persistent airflow obstruction (PAO, FEV1/FVC <70%) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on pulmonary function

    Time frame: Week 48

  11. Difference in St. George's Respiratory Questionnaire (SGRQ) scores (total and domain scores) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on quality of life

    Time frame: Week 48

  12. Change in SGRQ scores from baseline in the intervention group at Week 24 and Week 48

    To evaluate the effect of GDMT education on quality of life

    Time frame: Baseline, week 24, week 48

  13. Difference in the proportion of participants who achieved SGRQ MCID (decrease in total score ≥4 points) between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on quality of life

    Time frame: Week 48

  14. The proportion of participants achieved SGRQ MCID (decrease in total score ≥4 points) in the intervention group at Week 24 and 48

    To evaluate the effect of GDMT education on quality of life

    Time frame: Week 24, week 48

  15. Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on diagnosis rate

    Time frame: Week 48

  16. Difference in the time to written diagnosis of "Severe Asthma" between the intervention and control groups during the 48-week study period;

    To evaluate the effect of GDMT education on diagnosis rate

    Time frame: During the 48-week study period

  17. Reasons for not meeting the diagnostic criteriac for severe asthma among participants in the intervention group not diagnosed with "severe asthma" at Week 48

    To evaluate the effect of GDMT education on diagnosis rate

    Time frame: Week 48

  18. Difference in the proportion of participants with peripheral blood eosinophil (bEOS) test records within the past 3 months, excluding those during asthma exacerbation, between the intervention and control groups at Week 24 and 48

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: Week 24, week 48

  19. Difference in the proportion of participants with Fractional exhaled Nitric Oxide (FeNO) test records within the past 3 months between the intervention and control groups at Week 24 and 48

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: Week 24, week 48

  20. Difference in the proportion of participants with Immunoglobulin E (IgE) test records within the past 3 months between the intervention and control groups at Week 24 and 48

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: Week 24, week 48

  21. Difference in the cumulative number of bEOS test records between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: During the 48-week study period

  22. Difference in the cumulative number of IgE test records between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: During the 48-week study period

  23. Difference in the cumulative number of FeNO test records between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on biomarkers tests rate

    Time frame: During the 48-week study period

  24. Difference in the proportion of participants with typing records between the intervention and control groups over the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: Week 48

  25. Difference in the time to first asthma typing record between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: During the 48-week study period

  26. Difference in the proportion of participants with record of eosinophilic asthma phenotype between the intervention and control groups over the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: Week 48

  27. Difference in the time to first eosinophilic asthma phenotype record between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: During the 48-week study period

  28. Difference in the proportion of participants with a recorded Type 2 (T2) asthma phenotype between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: Week 48

  29. Difference in the proportion of participants with record of allergic asthma phenotype between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on typing records

    Time frame: Week 48

  30. Difference in the cumulative number of pulmonary function test records between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on pulmonary function test utilization

    Time frame: Week 48

  31. Difference in the proportion of participants using biologics between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on biologic utilization

    Time frame: Week 48

  32. Difference in the duration of biologic use between the intervention and control groups

    To evaluate the effect of GDMT education on biologic utilization

    Time frame: During the 48-week study period

  33. Distribution of different treatment pattern in the intervention group during the 48-week study period

    To evaluate the effect of GDMT education on treatment pattern

    Time frame: During the 48-week study period

  34. Distribution of different treatment pattern in the control group at Week 48

    To evaluate the effect of GDMT education on treatment pattern

    Time frame: Week 48

  35. Difference in the proportion of participants regularly completing scheduled follow-ups visitse between the intervention and control groups over the 48-week study period

    To evaluate the effect of GDMT education on regular follow-up visits

    Time frame: Week 48

  36. Difference in the drop-out rate between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on regular follow-up visits

    Time frame: Week 48

  37. Subgroup analyses will be conducted as appropriate; planned subgroups to explore include: Hospital classification, Participant classification.

    Describe the differences in physician behavior, participant benefit, and healthcare resource conservation across different hospital and participant subgroups after GDMT education

    Time frame: During the 48-week study period

Other outcomes

  1. Difference in the proportion of participants achieving clinical remission of asthma (CR3/CR4)f between the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on clinical remission of asthma

    Time frame: Week 48

  2. Characteristics of participants using biologics during the study period, including age, gender, disease duration, MH, insurance type, annual household income, asthma symptoms, comorbidities, EOS/FeNO/IgE levels, pulmonary function etc.

    To describe the characteristics of participants using biologics

    Time frame: During the 48-week study period

  3. Proportion of participants receiving maintenance OCS therapyi at Week 24 and 48

    To assess the effect of GDMT education on oral corticosteroid (OCS) use

    Time frame: Week 24, week 48

  4. Difference in the accumulative dose of maintenance OCS received between the intervention and control groups at Week 24 and 48

    To assess the effect of GDMT education on oral corticosteroid (OCS) use

    Time frame: Week 24, week 48

  5. Difference in the reduction of maintenance OCS dose among biologic users between the intervention and control groups at Week 48

    To assess the effect of GDMT education on oral corticosteroid (OCS) use

    Time frame: Week 48

  6. Difference in proportion of participants with asthma-related hospitalization between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: Week 48

  7. Difference in the average annual asthma-related hospitalization frequency between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  8. Difference in the average annual length of asthma-related hospital stay between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  9. Difference in proportion of participants with asthma-related ICU stay between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  10. Difference in the average annual length of asthma-related ICU stay between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  11. Difference in proportion of participants with asthma-related emergency department visits between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  12. Difference in the average number of emergency department visits between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  13. Difference in the number of prescribed medications types between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  14. Difference in the average annualized asthma-related medical costsj between the intervention and control groups during the 48-week study period

    To assess the effect of GDMT education on healthcare resource utilization

    Time frame: During the 48-week study period

  15. Difference in the change from baseline in Impulse Oscillometry (IOS) parameters (R5, R20, X5, Fres, AX) between the intervention and control groups at Week 24 and 48

    To evaluate the effect of GDMT education on pulmonary function (IOS)

    Time frame: Week 24, week 48

  16. Reasons for not initiating biologics in participants with severe asthma in the intervention group during the study period

    To describe reasons for not initiating biologics in severe asthma during the study period, and reasons for participants discontinuing biologics

    Time frame: During the 48-week study period

  17. Reasons for discontinuing biologics in intervention group during the study period

    To describe reasons for not initiating biologics in severe asthma during the study period, and reasons for participants discontinuing biologics

    Time frame: During the 48-week study period

  18. Difference in number of asthma-related comorbidities typesk in written records between the intervention and control groups during the 48-week study period

    To evaluate the effect of GDMT education on comorbidity recording

    Time frame: During the 48-week study period

  19. Treatment satisfaction in the intervention and control groups at Week 48

    To evaluate the effect of GDMT education on participant treatment satisfaction

    Time frame: Week 48

07

Study locations

1 of 20 sites recruiting
  • Research Site
    Chengdu, 611130, China
    Not yet recruiting
  • Research Site
    Chifeng, 024206, China
    Recruiting
  • Research Site
    Dongyang, 322100, China
    Not yet recruiting
  • Research Site
    Hefei, 133500, China
    Not yet recruiting
  • Research Site
    Hefei, 230041, China
    Not yet recruiting
  • Research Site
    Hengyang, 421001, China
    Not yet recruiting
  • Research Site
    Heze, 274099, China
    Not yet recruiting
  • Research Site
    Jiaxing, 314001, China
    Not yet recruiting
  • Research Site
    Langfang, 065000, China
    Not yet recruiting
  • Research Site
    Meizhou, 514031, China
    Not yet recruiting
  • Research Site
    Quanzhou, 362000, China
    Not yet recruiting
  • Research Site
    Shanghai, 200433, China
    Not yet recruiting
  • Research Site
    Shiyan, 442000, China
    Not yet recruiting
  • Research Site
    Tai’an, 271000, China
    Not yet recruiting
  • Research Site
    Ürümqi, 830054, China
    Not yet recruiting
  • Research Site
    Xi'an, 710114, China
    Not yet recruiting
  • Research Site
    Yantai, 264000, China
    Not yet recruiting
  • Research Site
    Yongzhou, 426100, China
    Not yet recruiting
  • Research Site
    Yunnan, 661000, China
    Not yet recruiting
  • Research Site
    Zhanjiang, 524001, China
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2028, 19 months after the start.

Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 19 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 22, 2026
StartActual
Sep 5, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07718724
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Sep 5, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
Kewu Huang
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion